{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:28:43Z","timestamp":1792636123802,"version":"4.5.0"},"reference-count":221,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1038\/s41575-022-00617-7","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T07:09:39Z","timestamp":1652425779000},"page":"585-604","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Genetics, pathobiology and therapeutic opportunities of polycystic liver disease"],"prefix":"10.1038","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1358-5429","authenticated-orcid":false,"given":"Paula","family":"Olaizola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6193-7436","authenticated-orcid":false,"given":"Pedro M.","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6160-5906","authenticated-orcid":false,"given":"Francisco J.","family":"Caballero-Camino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Izquierdo-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3553-1755","authenticated-orcid":false,"given":"Patricia","family":"Aspichueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4353-9968","authenticated-orcid":false,"given":"Luis","family":"Bujanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas F.","family":"Larusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost P. H.","family":"Drenth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Perugorria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5224-2373","authenticated-orcid":false,"given":"Jesus M.","family":"Banales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"key":"617_CR1","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jhep.2017.11.024","volume":"68","author":"RMM van Aerts","year":"2018","unstructured":"van Aerts, R. M. M., van de Laarschot, L. F. M., Banales, J. M. & Drenth, J. P. H. Clinical management of polycystic liver disease. J. Hepatol. 68, 827\u2013837 (2018).","journal-title":"J. Hepatol."},{"key":"617_CR2","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nrgastro.2014.155","volume":"11","author":"M Perugorria","year":"2014","unstructured":"Perugorria, M. et al. Polycystic liver diseases: advanced insights into the molecular mechanisms. Nat. Rev. Gastroenterol. Hepatol. 11, 750\u2013761 (2014).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"617_CR3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.4254\/wjh.v12.i3.72","volume":"12","author":"Z Zhang","year":"2020","unstructured":"Zhang, Z., Wang, Z. & Huang, Y. Polycystic liver disease: classification, diagnosis, treatment process, and clinical management. World J. Hepatol. 12, 72\u201383 (2020).","journal-title":"World J. Hepatol."},{"key":"617_CR4","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1111\/j.1572-0241.2005.00263.x","volume":"100","author":"H Arnold","year":"2005","unstructured":"Arnold, H. & Harrison, S. New advances in evaluation and management of patients with polycystic liver disease. Am. J. Gastroenterol. 100, 2569\u20132582 (2005).","journal-title":"Am. J. Gastroenterol."},{"key":"617_CR5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/j.1478-3231.2010.02247.x","volume":"31","author":"L Van Keimpema","year":"2011","unstructured":"Van Keimpema, L. et al. Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases. Liver Int. 31, 92\u201398 (2011).","journal-title":"Liver Int."},{"key":"617_CR6","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/hep.29582","volume":"68","author":"L Barbier","year":"2018","unstructured":"Barbier, L. et al. Polycystic liver disease: hepatic venous outflow obstruction lesions of the noncystic parenchyma have major consequences. Hepatology 68, 652\u2013662 (2018).","journal-title":"Hepatology"},{"key":"617_CR7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/cld.1001","volume":"17","author":"D Brandman","year":"2021","unstructured":"Brandman, D. Jaundice in polycystic liver disease: more than meets the eye. Clin. Liver Dis. 17, 165\u2013168 (2021).","journal-title":"Clin. Liver Dis."},{"key":"617_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1177\/2050640617705577","volume":"6","author":"M Neijenhuis","year":"2018","unstructured":"Neijenhuis, M. et al. Impact of liver volume on polycystic liver disease-related symptoms and quality of life. United European Gastroenterol. J. 6, 81\u201388 (2018).","journal-title":"United European Gastroenterol. J."},{"key":"617_CR9","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1080\/17474124.2017.1309280","volume":"11","author":"M Wong","year":"2017","unstructured":"Wong, M., McCaughan, G. & Strasser, S. An update on the pathophysiology and management of polycystic liver disease. Expert Rev. Gastroenterol. Hepatol. 11, 569\u2013581 (2017).","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"617_CR10","doi-asserted-by":"publisher","first-page":"100166","DOI":"10.1016\/j.jhepr.2020.100166","volume":"2","author":"T Suwabe","year":"2020","unstructured":"Suwabe, T. et al. Epidemiology of autosomal-dominant polycystic liver disease in Olmsted county. JHEP Rep. 2, 100166 (2020).","journal-title":"JHEP Rep."},{"key":"617_CR11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/ki.2009.128","volume":"76","author":"V Torres","year":"2009","unstructured":"Torres, V. & Harris, P. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int. 76, 149\u2013168 (2009).","journal-title":"Kidney Int."},{"key":"617_CR12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12882-015-0002-z","volume":"16","author":"K Ebner","year":"2015","unstructured":"Ebner, K. et al. Rationale, design and objectives of ARegPKD, a European ARPKD registry study. BMC Nephrol. 16, 22 (2015).","journal-title":"BMC Nephrol."},{"key":"617_CR13","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/liv.13965","volume":"39","author":"R van Aerts","year":"2019","unstructured":"van Aerts, R. et al. Severity in polycystic liver disease is associated with aetiology and female gender: results of the International PLD Registry. Liver Int. 39, 575\u2013582 (2019).","journal-title":"Liver Int."},{"key":"617_CR14","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1432-2277.2011.01360.x","volume":"24","author":"L van Keimpema","year":"2011","unstructured":"van Keimpema, L. et al. Excellent survival after liver transplantation for isolated polycystic liver disease: an European Liver Transplant Registry study. Transplant. Int. 24, 1239\u20131245 (2011).","journal-title":"Transplant. Int."},{"key":"617_CR15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/tri.12875","volume":"30","author":"H D\u2019Agnolo","year":"2017","unstructured":"D\u2019Agnolo, H. et al. Center is an important indicator for choice of invasive therapy in polycystic liver disease. Transplant. Int. 30, 76\u201382 (2017).","journal-title":"Transplant. Int."},{"key":"617_CR16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2215\/CJN.00080605","volume":"1","author":"K Bae","year":"2006","unstructured":"Bae, K. et al. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin. J. Am. Soc. Nephrol. 1, 64\u201369 (2006).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"617_CR17","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1111\/liv.14986","volume":"41","author":"S Aapkes","year":"2021","unstructured":"Aapkes, S. et al. Estrogens in polycystic liver disease: a target for future therapies? Liver Int. 41, 2009\u20132019 (2021).","journal-title":"Liver Int."},{"key":"617_CR18","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1002\/cpt.1553","volume":"106","author":"RMM van Aerts","year":"2019","unstructured":"van Aerts, R. M. M. et al. Estrogen-containing oral contraceptives are associated with polycystic liver disease severity in premenopausal patients. Clin. Pharmacol. Ther. 106, 1338\u20131345 (2019).","journal-title":"Clin. Pharmacol. Ther."},{"key":"617_CR19","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/0092-8674(94)90137-6","volume":"77","author":"The European Polycystic Kidney Disease Consortium.","year":"1994","unstructured":"The European Polycystic Kidney Disease Consortium. The polycystic kidney disease 1 gene encodes a 14\u2009kb transcript and lies within a duplicated region on chromosome 16. Cell 77, 881\u2013894 (1994).","journal-title":"Cell"},{"key":"617_CR20","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/hep.1840110619","volume":"11","author":"P Gabow","year":"1990","unstructured":"Gabow, P. et al. Risk factors for the development of hepatic cysts in autosomal dominant polycystic kidney disease. Hepatology 11, 1033\u20131037 (1990).","journal-title":"Hepatology"},{"key":"617_CR21","first-page":"1282","volume":"26","author":"R Sherstha","year":"1997","unstructured":"Sherstha, R. et al. Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease. Hepatology 26, 1282\u20131286 (1997).","journal-title":"Hepatology"},{"key":"617_CR22","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1126\/science.272.5266.1339","volume":"272","author":"T Mochizuki","year":"1996","unstructured":"Mochizuki, T. et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 272, 1339\u20131342 (1996).","journal-title":"Science"},{"key":"617_CR23","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1681\/ASN.2019030298","volume":"30","author":"W Besse","year":"2019","unstructured":"Besse, W. et al. ALg9 mutation carriers develop kidney and liver cysts. J. Am. Soc. Nephrol. 30, 2091\u20132102 (2019).","journal-title":"J. Am. Soc. Nephrol."},{"key":"617_CR24","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.ajhg.2018.03.013","volume":"102","author":"E Cornec-Le Gall","year":"2018","unstructured":"Cornec-Le Gall, E. et al. Monoallelic mutations to DNAJB11 cause atypical autosomal-dominant polycystic kidney disease. Am. J. Hum. Genet. 102, 832\u2013844 (2018).","journal-title":"Am. J. Hum. Genet."},{"key":"617_CR25","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.kint.2020.02.022","volume":"98","author":"VT Huynh","year":"2020","unstructured":"Huynh, V. T. et al. Clinical spectrum, prognosis and estimated prevalence of DNAJB11-kidney disease. Kidney Int. 98, 476\u2013487 (2020).","journal-title":"Kidney Int."},{"key":"617_CR26","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.ajhg.2016.05.004","volume":"98","author":"B Porath","year":"2016","unstructured":"Porath, B. et al. Mutations in GANAB, encoding the glucosidase II\u03b1 subunit, cause autosomal-dominant polycystic kidney and liver disease. Am. J. Hum. Genet. 98, 1193\u20131207 (2016).","journal-title":"Am. J. Hum. Genet."},{"key":"617_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01585-4","volume":"15","author":"L van de Laarschot","year":"2020","unstructured":"van de Laarschot, L. et al. Novel GANAB variants associated with polycystic liver disease. Orphanet J. Rare Dis. 15, 302 (2020).","journal-title":"Orphanet J. Rare Dis."},{"key":"617_CR28","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/ejhg.2015.86","volume":"24","author":"W Cnossen","year":"2016","unstructured":"Cnossen, W. et al. LRP5 variants may contribute to ADPKD. Eur. J. Hum. Genet. 24, 237\u2013242 (2016).","journal-title":"Eur. J. Hum. Genet."},{"key":"617_CR29","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/ng833","volume":"30","author":"CJ Ward","year":"2002","unstructured":"Ward, C. J. et al. The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat. Genet. 30, 259\u2013269 (2002).","journal-title":"Nat. Genet."},{"key":"617_CR30","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/ng.3871","volume":"49","author":"H Lu","year":"2017","unstructured":"Lu, H. et al. Mutations in DZIP1L, which encodes a ciliary-transition-zone protein, cause autosomal recessive polycystic kidney disease. Nat. Genet. 49, 1025\u20131034 (2017).","journal-title":"Nat. Genet."},{"key":"617_CR31","doi-asserted-by":"publisher","first-page":"104160","DOI":"10.1016\/j.ejmg.2021.104160","volume":"64","author":"MM Boerrigter","year":"2021","unstructured":"Boerrigter, M. M., Bongers, E. M. H. F., Lugtenberg, D., Nevens, F. & Drenth, J. P. H. Polycystic liver disease genes: practical considerations for genetic testing. Eur. J. Med. Genet. 64, 104160 (2021).","journal-title":"Eur. J. Med. Genet."},{"key":"617_CR32","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/ng1104","volume":"33","author":"JPH Drenth","year":"2003","unstructured":"Drenth, J. P. H., Te Morsche, R. H. M., Smink, R., Bonifacino, J. S. & Jansen, J. B. M. J. Germline mutations in PRKCSH are associated with autosomal dominant polycystic liver disease. Nat. Genet. 33, 345\u2013347 (2003).","journal-title":"Nat. Genet."},{"key":"617_CR33","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/ng1357","volume":"36","author":"S Davila","year":"2004","unstructured":"Davila, S. et al. Mutations in SEC63 cause autosomal dominant polycystic liver disease. Nat. Genet. 36, 575\u2013577 (2004).","journal-title":"Nat. Genet."},{"key":"617_CR34","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1172\/JCI90129","volume":"127","author":"W Besse","year":"2017","unstructured":"Besse, W. et al. Isolated polycystic liver disease genes define effectors of polycystin-1 function. J. Clin. Invest. 127, 1772\u20131785 (2017).","journal-title":"J. Clin. Invest."},{"key":"617_CR35","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1002\/humu.23383","volume":"39","author":"W Besse","year":"2018","unstructured":"Besse, W. et al. A noncoding variant in GANAB explains isolated polycystic liver disease (PCLD) in a large family. Hum. Mutat. 39, 378\u2013382 (2018).","journal-title":"Hum. Mutat."},{"key":"617_CR36","doi-asserted-by":"publisher","first-page":"5343","DOI":"10.1073\/pnas.1309438111","volume":"111","author":"WR Cnossen","year":"2014","unstructured":"Cnossen, W. R. et al. Whole-exome sequencing reveals LRP5 mutations and canonical Wnt signaling associated with hepatic cystogenesis. Proc. Natl Acad. Sci. USA 111, 5343\u20135348 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"617_CR37","doi-asserted-by":"publisher","first-page":"120","DOI":"10.21037\/atm-20-3318","volume":"9","author":"J Wang","year":"2021","unstructured":"Wang, J., Yang, H., Guo, R., Sang, X. & Mao, Y. Association of a novel PKHD1 mutation in a family with autosomal dominant polycystic liver disease. Ann. Transl. Med. 9, 120\u2013120 (2021).","journal-title":"Ann. Transl. Med."},{"key":"617_CR38","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1172\/JCI76972","volume":"125","author":"VG Gainullin","year":"2015","unstructured":"Gainullin, V. G., Hopp, K., Ward, C. J., Hommerding, C. J. & Harris, P. C. Polycystin-1 maturation requires polycystin-2 in a dose-dependent manner. J. Clin. Invest. 125, 607\u2013620 (2015).","journal-title":"J. Clin. Invest."},{"key":"617_CR39","doi-asserted-by":"publisher","first-page":"G500","DOI":"10.1152\/ajpgi.00064.2006","volume":"291","author":"BQ Huang","year":"2006","unstructured":"Huang, B. Q. et al. Isolation and characterization of cholangiocyte primary cilia. Am. J. Physiol. Gastrointest. Liver Physiol. 291, G500\u2013G509 (2006).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"617_CR40","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/ncb754","volume":"4","author":"P Koulen","year":"2002","unstructured":"Koulen, P. et al. Polycystin-2 is an intracellular calcium release channel. Nat. Cell Biol. 4, 191\u2013197 (2002).","journal-title":"Nat. Cell Biol."},{"key":"617_CR41","doi-asserted-by":"publisher","first-page":"6454","DOI":"10.1073\/pnas.0610324104","volume":"104","author":"GI Anyatonwu","year":"2007","unstructured":"Anyatonwu, G. I., Estrada, M., Tian, X., Somlo, S. & Ehrlich, B. E. Regulation of ryanodine receptor-dependent calcium signaling by polycystin-2. Proc. Natl Acad. Sci. USA 104, 6454\u20136459 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"617_CR42","doi-asserted-by":"publisher","first-page":"41298","DOI":"10.1074\/jbc.M510082200","volume":"280","author":"Y Li","year":"2005","unstructured":"Li, Y., Wright, J. M., Qian, F., Germino, G. G. & Guggino, W. B. Polycystin 2 interacts with type I inositol 1,4,5-trisphosphate receptor to modulate intracellular Ca2+ signaling. J. Biol. Chem. 280, 41298\u201341306 (2005).","journal-title":"J. Biol. Chem."},{"key":"617_CR43","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1093\/hmg\/ddl404","volume":"15","author":"Y Wu","year":"2006","unstructured":"Wu, Y. et al. Kinesin-2 mediates physical and functional interactions between polycystin-2 and fibrocystin. Hum. Mol. Genet. 15, 3280\u20133292 (2006).","journal-title":"Hum. Mol. Genet."},{"key":"617_CR44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.devcel.2009.06.016","volume":"17","author":"BT MacDonald","year":"2009","unstructured":"MacDonald, B. T., Tamai, K. & He, X. Wnt\/\u03b2-catenin signaling: components, mechanisms, and diseases. Dev. Cell 17, 9\u201326 (2009).","journal-title":"Dev. Cell"},{"key":"617_CR45","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41575-018-0075-9","volume":"16","author":"M Perugorria","year":"2019","unstructured":"Perugorria, M. et al. Wnt-\u03b2-catenin signalling in liver development, health and disease. Nat. Rev. Gastroenterol. Hepatol. 16, 121\u2013136 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"617_CR46","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/ncb3363","volume":"18","author":"S Kim","year":"2016","unstructured":"Kim, S. et al. The polycystin complex mediates Wnt\/Ca2+ signalling. Nat. Cell Biol. 18, 752\u2013764 (2016).","journal-title":"Nat. Cell Biol."},{"key":"617_CR47","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1002\/hep.26554","volume":"58","author":"C Spirli","year":"2013","unstructured":"Spirli, C. et al. Protein kinase A-dependent pSer(675)-\u03b2-catenin, a novel signaling defect in a mouse model of congenital hepatic fibrosis. Hepatology 58, 1713\u20131723 (2013).","journal-title":"Hepatology"},{"key":"617_CR48","doi-asserted-by":"publisher","first-page":"887","DOI":"10.3389\/fphys.2017.00887","volume":"8","author":"S Lang","year":"2017","unstructured":"Lang, S. et al. An update on Sec 61 channel functions, mechanisms, and related diseases. Front. Physiol. 8, 887 (2017).","journal-title":"Front. Physiol."},{"key":"617_CR49","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1146\/annurev-biophys-050511-102312","volume":"41","author":"E Park","year":"2012","unstructured":"Park, E. & Rapoport, T. A. Mechanisms of Sec61SecY-mediated protein translocation across membranes. Annu. Rev. Biophys. 41, 21\u201340 (2012).","journal-title":"Annu. Rev. Biophys."},{"key":"617_CR50","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1074\/jbc.REV118.002804","volume":"294","author":"KFR Pobre","year":"2019","unstructured":"Pobre, K. F. R., Poet, G. J. & Hendershot, L. M. The endoplasmic reticulum (ER) chaperone BiP is a master regulator of ER functions: getting by with a little help from ERdj friends. J. Biol. Chem. 294, 2098\u20132108 (2019).","journal-title":"J. Biol. Chem."},{"key":"617_CR51","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1016\/j.bbamcr.2013.04.001","volume":"1833","author":"M Aebi","year":"2013","unstructured":"Aebi, M. N-linked protein glycosylation in the ER. Biochim. Biophys. Acta 1833, 2430\u20132437 (2013).","journal-title":"Biochim. Biophys. Acta"},{"key":"617_CR52","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2174\/1389203716666150213160438","volume":"16","author":"C D\u2019Alessio","year":"2015","unstructured":"D\u2019Alessio, C. & Dahms, N. M. Glucosidase II and MRH-domain containing proteins in the secretory pathway. Curr. Protein Pept. Sci. 16, 31\u201348 (2015).","journal-title":"Curr. Protein Pept. Sci."},{"key":"617_CR53","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.semcdb.2014.12.001","volume":"41","author":"A Tannous","year":"2015","unstructured":"Tannous, A., Pisoni, G. B., Hebert, D. N. & Molinari, M. N-linked sugar-regulated protein folding and quality control in the ER. Semin. Cell Dev. Biol. 41, 79\u201389 (2015).","journal-title":"Semin. Cell Dev. Biol."},{"key":"617_CR54","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/ng.860","volume":"43","author":"SV Fedeles","year":"2011","unstructured":"Fedeles, S. V. et al. A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation. Nat. Genet. 43, 639\u2013647 (2011).","journal-title":"Nat. Genet."},{"key":"617_CR55","doi-asserted-by":"publisher","first-page":"20763","DOI":"10.1074\/jbc.M107788200","volume":"277","author":"LJ Newby","year":"2002","unstructured":"Newby, L. J. et al. Identification, characterization, and localization of a novel kidney polycystin-1-polycystin-2 complex. J. Biol. Chem. 277, 20763\u201320773 (2002).","journal-title":"J. Biol. Chem."},{"key":"617_CR56","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrgastro.2012.254","volume":"10","author":"TJG Gevers","year":"2013","unstructured":"Gevers, T. J. G. & Drenth, J. P. H. Diagnosis and management of polycystic liver disease. Nat. Rev. Gastroenterol. Hepatol. 10, 101\u2013108 (2013).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"617_CR57","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.molmed.2014.01.003","volume":"20","author":"ES Wills","year":"2014","unstructured":"Wills, E. S., Roepman, R. & Drenth, J. P. H. Polycystic liver disease: ductal plate malformation and the primary cilium. Trends Mol. Med. 20, 261\u2013270 (2014).","journal-title":"Trends Mol. Med."},{"key":"617_CR58","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1002\/hep.24292","volume":"53","author":"P Raynaud","year":"2011","unstructured":"Raynaud, P. et al. A classification of ductal plate malformations based on distinct pathogenic mechanisms of biliary dysmorphogenesis. Hepatology 53, 1959\u20131966 (2011).","journal-title":"Hepatology"},{"key":"617_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-pathmechdis-012418-013013","volume":"15","author":"FP Lemaigre","year":"2020","unstructured":"Lemaigre, F. P. Development of the intrahepatic and extrahepatic biliary tract: a framework for understanding congenital diseases. Annu. Rev. Pathol. 15, 1\u201322 (2020).","journal-title":"Annu. Rev. Pathol."},{"key":"617_CR60","doi-asserted-by":"publisher","first-page":"5775","DOI":"10.3748\/wjg.v19.i35.5775","volume":"19","author":"B Abu-Wasel","year":"2013","unstructured":"Abu-Wasel, B., Walsh, C., Keough, V. & Molinari, M. Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases. World J. Gastroenterol. 19, 5775\u20135786 (2013).","journal-title":"World J. Gastroenterol."},{"key":"617_CR61","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1053\/j.gastro.2011.08.004","volume":"141","author":"MJ Janssen","year":"2011","unstructured":"Janssen, M. J. et al. Secondary, somatic mutations might promote cyst formation in patients with autosomal dominant polycystic liver disease. Gastroenterology 141, 2056\u20132063.e2 (2011).","journal-title":"Gastroenterology"},{"key":"617_CR62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132295","volume":"10","author":"JB Beaudry","year":"2015","unstructured":"Beaudry, J. B. et al. Proliferation-independent initiation of biliary cysts in polycystic liver diseases. PLoS ONE 10, e0132295 (2015).","journal-title":"PLoS ONE"},{"key":"617_CR63","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/hep.1840400404","volume":"40","author":"GT Everson","year":"2004","unstructured":"Everson, G. T., Taylor, M. R. G. & Doctor, R. B. Polycystic disease of the liver. Hepatology 40, 774\u2013782 (2004).","journal-title":"Hepatology"},{"key":"617_CR64","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.2353\/ajpath.2007.070337","volume":"171","author":"Y Sato","year":"2007","unstructured":"Sato, Y. et al. Cholangiocytes with mesenchymal features contribute to progressive hepatic fibrosis of the polycystic kidney rat. Am. J. Pathol. 171, 1859\u20131871 (2007).","journal-title":"Am. J. Pathol."},{"key":"617_CR65","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/path.2734","volume":"222","author":"S Hassane","year":"2010","unstructured":"Hassane, S. et al. Elevated TGF\u03b2-Smad signalling in experimental Pkd1 models and human patients with polycystic kidney disease. J. Pathol. 222, 21\u201331 (2010).","journal-title":"J. Pathol."},{"key":"617_CR66","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1002\/dvdy.21520","volume":"237","author":"M Yanai","year":"2008","unstructured":"Yanai, M. et al. FGF signaling segregates biliary cell-lineage from chick hepatoblasts cooperatively with BMP4 and ECM components in vitro. Dev. Dyn. 237, 1268\u20131283 (2008).","journal-title":"Dev. Dyn."},{"key":"617_CR67","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/nature07753","volume":"458","author":"JM Neugebauer","year":"2009","unstructured":"Neugebauer, J. M., Amack, J. D., Peterson, A. G., Bisgrove, B. W. & Yost, H. J. FGF signalling during embryo development regulates cilia length in diverse epithelia. Nature 458, 651\u2013654 (2009).","journal-title":"Nature"},{"key":"617_CR68","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/ki.2010.375","volume":"79","author":"I Pavik","year":"2011","unstructured":"Pavik, I. et al. Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate. Kidney Int. 79, 234\u2013240 (2011).","journal-title":"Kidney Int."},{"key":"617_CR69","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.cell.2011.05.030","volume":"145","author":"EJ Ezratty","year":"2011","unstructured":"Ezratty, E. J. et al. A role for the primary cilium in notch signaling and epidermal differentiation during skin development. Cell 145, 1129\u20131141 (2011).","journal-title":"Cell"},{"key":"617_CR70","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1242\/dev.054452","volume":"137","author":"SS Lopes","year":"2010","unstructured":"Lopes, S. S. et al. Notch signalling regulates left-right asymmetry through ciliary length control. Development 137, 3625\u20133632 (2010).","journal-title":"Development"},{"key":"617_CR71","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1242\/dev.078634","volume":"139","author":"HP Shih","year":"2012","unstructured":"Shih, H. P. et al. A Notch-dependent molecular circuitry initiates pancreatic endocrine and ductal cell differentiation. Development 139, 2488\u20132499 (2012).","journal-title":"Development"},{"key":"617_CR72","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/hep.21952","volume":"47","author":"T Decaens","year":"2008","unstructured":"Decaens, T. et al. Stabilization of \u03b2-catenin affects mouse embryonic liver growth and hepatoblast fate. Hepatology 47, 247\u2013258 (2008).","journal-title":"Hepatology"},{"key":"617_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/2046-2530-1-7","volume":"1","author":"HL May-Simera","year":"2012","unstructured":"May-Simera, H. L. & Kelley, M. W. Cilia, Wnt signaling, and the cytoskeleton. Cilia 1, 7 (2012).","journal-title":"Cilia"},{"key":"617_CR74","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1681\/ASN.2006121355","volume":"18","author":"T Benzing","year":"2007","unstructured":"Benzing, T., Simons, M. & Walz, G. Wnt signaling in polycystic kidney disease. J. Am. Soc. Nephrol. 18, 1389\u20131398 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"617_CR75","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1242\/dev.129.8.1819","volume":"129","author":"M Clotman","year":"2007","unstructured":"Clotman, M. et al. The onecut transcription factor HNF6 is required for normal development of the biliary tract. Development 129, 1819\u20131828 (2007).","journal-title":"Development"},{"key":"617_CR76","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ydbio.2007.05.028","volume":"308","author":"MP Hunter","year":"2007","unstructured":"Hunter, M. P. et al. The homeobox gene Hhex is essential for proper hepatoblast differentiation and bile duct morphogenesis. Dev. Biol. 308, 355\u2013367 (2007).","journal-title":"Dev. Biol."},{"key":"617_CR77","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1053\/j.gastro.2005.12.005","volume":"130","author":"CE Pierreux","year":"2006","unstructured":"Pierreux, C. E. et al. The transcription factor hepatocyte nuclear factor-6 controls the development of pancreatic ducts in the mouse. Gastroenterology 130, 532\u2013541 (2006).","journal-title":"Gastroenterology"},{"key":"617_CR78","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1172\/JCI0214099","volume":"109","author":"X Hou","year":"2002","unstructured":"Hou, X. et al. Cystin, a novel cilia-associated protein, is disrupted in the cpk mouse model of polycystic kidney disease. J. Clin. Invest. 109, 533\u2013540 (2002).","journal-title":"J. Clin. Invest."},{"key":"617_CR79","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1172\/JCI200420083","volume":"113","author":"T Hiesberger","year":"2004","unstructured":"Hiesberger, T. et al. Mutation of hepatocyte nuclear factor\u20131\u03b2 inhibits Pkhd1 gene expression and produces renal cysts in mice. J. Clin. Invest. 113, 814\u2013825 (2004).","journal-title":"J. Clin. Invest."},{"key":"617_CR80","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1038\/sj.emboj.7600160","volume":"23","author":"L Gresh","year":"2004","unstructured":"Gresh, L. et al. A transcriptional network in polycystic kidney disease. EMBO J. 23, 1657\u20131668 (2004).","journal-title":"EMBO J."},{"key":"617_CR81","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.1242\/dev.02591","volume":"133","author":"H Yamasaki","year":"2006","unstructured":"Yamasaki, H. et al. Suppression of C\/EBP\u03b1 expression in periportal hepatoblasts may stimulate biliary cell differentiation through increased Hnf6 and Hnf1b expression. Development 133, 4233\u20134243 (2006).","journal-title":"Development"},{"key":"617_CR82","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1053\/j.gastro.2008.12.006","volume":"136","author":"NJ Hand","year":"2009","unstructured":"Hand, N. J. et al. The microRNA-30 family is required for vertebrate hepatobiliary development. Gastroenterology 136, 1081\u20131090 (2009).","journal-title":"Gastroenterology"},{"key":"617_CR83","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S1665-2681(19)31406-1","volume":"11","author":"N Chandok","year":"2012","unstructured":"Chandok, N. Polycystic liver disease: a clinical review. Ann. Hepatol. 11, 819\u201326 (2012).","journal-title":"Ann. Hepatol."},{"key":"617_CR84","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/MOG.0000000000000514","volume":"35","author":"PY Lee-Law","year":"2019","unstructured":"Lee-Law, P. Y., Van De Laarschot, L. F. M., Banales, J. M. & Drenth, J. P. H. Genetics of polycystic liver diseases. Curr. Opin. Gastroenterol. 35, 65\u201372 (2019).","journal-title":"Curr. Opin. Gastroenterol."},{"key":"617_CR85","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1038\/ejhg.2016.97","volume":"24","author":"E Wills","year":"2016","unstructured":"Wills, E. et al. Chromosomal abnormalities in hepatic cysts point to novel polycystic liver disease genes. Eur. J. Hum. Genet. 24, 1707\u20131714 (2016).","journal-title":"Eur. J. Hum. Genet."},{"key":"617_CR86","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.34067\/KID.0002522020","volume":"1","author":"W Besse","year":"2020","unstructured":"Besse, W. et al. Adult inactivation of the recessive polycystic kidney disease gene causes polycystic liver disease. Kidney360 1, 1068\u20131076 (2020).","journal-title":"Kidney360"},{"key":"617_CR87","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050324","volume":"7","author":"MJ Janssen","year":"2012","unstructured":"Janssen, M. J., Salomon, J., te Morsche, R. H. M. & Drenth, J. P. H. Loss of heterozygosity is present in sec63 germline carriers with polycystic liver disease. PLoS ONE 7, e50324 (2012).","journal-title":"PLoS ONE"},{"key":"617_CR88","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1136\/gutjnl-2014-308062","volume":"64","author":"MJ Janssen","year":"2015","unstructured":"Janssen, M. J. et al. Somatic loss of polycystic disease genes contributes to the formation of isolated and polycystic liver cysts. Gut 64, 688\u2013690 (2015).","journal-title":"Gut"},{"key":"617_CR89","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3748\/wjg.v19.i1.141","volume":"19","author":"JM Banales","year":"2013","unstructured":"Banales, J. M., Munoz-Garrido, P. & Bujanda, L. Somatic second-hit mutations leads to polycystic liver diseases. World J. Gastroenterol. 19, 141\u2013143 (2013).","journal-title":"World J. Gastroenterol."},{"key":"617_CR90","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1681\/ASN.V1071524","volume":"10","author":"Y Pei","year":"1999","unstructured":"Pei, Y. et al. Somatic PKD2 mutations in individual kidney and liver cysts support a \u2018two-hit\u2019 model of cystogenesis in type 2 autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 10, 1524\u20131529 (1999).","journal-title":"J. Am. Soc. Nephrol."},{"key":"617_CR91","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1097-2765(00)80135-5","volume":"2","author":"TJ Watnick","year":"1998","unstructured":"Watnick, T. J. et al. Somatic mutation in individual liver cysts supports a two-hit model of cystogenesis in autosomal dominant polycystic kidney disease. Mol. Cell 2, 247\u2013251 (1998).","journal-title":"Mol. Cell"},{"key":"617_CR92","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1055\/s-0036-1597817","volume":"37","author":"A Santos-Laso","year":"2017","unstructured":"Santos-Laso, A. et al. New advances in polycystic liver diseases. Semin. Liver Dis. 37, 45\u201355 (2017).","journal-title":"Semin. Liver Dis."},{"key":"617_CR93","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1053\/j.gastro.2006.07.003","volume":"131","author":"AI Masyuk","year":"2006","unstructured":"Masyuk, A. I. et al. Cholangiocyte cilia detect changes in luminal fluid flow and transmit them into intracellular Ca2+ and cAMP signaling. Gastroenterology 131, 911\u2013920 (2006).","journal-title":"Gastroenterology"},{"key":"617_CR94","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.2353\/ajpath.2008.080125","volume":"173","author":"JM Banales","year":"2008","unstructured":"Banales, J. M. et al. Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease. Am. J. Pathol. 173, 1637\u20131646 (2008).","journal-title":"Am. J. Pathol."},{"key":"617_CR95","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jhep.2016.10.032","volume":"66","author":"C Spirli","year":"2017","unstructured":"Spirli, C. et al. Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease. J. Hepatol. 66, 571\u2013580 (2017).","journal-title":"J. Hepatol."},{"key":"617_CR96","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/hep.22636","volume":"49","author":"JM Banales","year":"2009","unstructured":"Banales, J. M. et al. The cAMP effectors Epac and protein kinase A (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD). Hepatology 49, 160\u2013174 (2009).","journal-title":"Hepatology"},{"key":"617_CR97","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1053\/j.gastro.2010.04.010","volume":"139","author":"S Gradilone","year":"2010","unstructured":"Gradilone, S. et al. Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD. Gastroenterology 139, 304\u2013314.e2 (2010).","journal-title":"Gastroenterology"},{"key":"617_CR98","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.jhep.2015.05.023","volume":"63","author":"P Munoz-Garrido","year":"2015","unstructured":"Munoz-Garrido, P. et al. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease. J. Hepatol. 63, 952\u2013961 (2015).","journal-title":"J. Hepatol."},{"key":"617_CR99","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1053\/j.gastro.2006.12.039","volume":"132","author":"T Masyuk","year":"2007","unstructured":"Masyuk, T., Masyuk, A., Torres, V., Harris, P. & Larusso, N. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3\u2032,5\u2032-cyclic monophosphate. Gastroenterology 132, 1104\u20131116 (2007).","journal-title":"Gastroenterology"},{"key":"617_CR100","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/hep.26140","volume":"58","author":"T Masyuk","year":"2013","unstructured":"Masyuk, T. et al. Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology 58, 409\u2013421 (2013).","journal-title":"Hepatology"},{"key":"617_CR101","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1159\/000450989","volume":"35","author":"M Perugorria","year":"2017","unstructured":"Perugorria, M. et al. Bile acids in polycystic liver diseases: triggers of disease progression and potential solution for treatment. Dig. Dis. 35, 275\u2013281 (2017).","journal-title":"Dig. Dis."},{"key":"617_CR102","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/1389200216666151103115454","volume":"17","author":"J Marin","year":"2015","unstructured":"Marin, J., Macias, R., Briz, O., Banales, J. & Monte, M. Bile acids in physiology, pathology and pharmacology. Curr. Drug Metab. 17, 4\u201329 (2015).","journal-title":"Curr. Drug Metab."},{"key":"617_CR103","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1002\/hep.29284","volume":"66","author":"TV Masyuk","year":"2017","unstructured":"Masyuk, T. V. et al. TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate\/G\u03b1s signaling. Hepatology 66, 1197\u20131218 (2017).","journal-title":"Hepatology"},{"key":"617_CR104","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1136\/gutjnl-2015-309458","volume":"65","author":"M Reich","year":"2016","unstructured":"Reich, M. et al. TGR5 is essential for bile acid-dependent cholangiocyte proliferation in vivo and in vitro. Gut 65, 487\u2013501 (2016).","journal-title":"Gut"},{"key":"617_CR105","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0002-9440(10)62231-6","volume":"166","author":"Y Sato","year":"2005","unstructured":"Sato, Y. et al. Activation of the MEK5\/ERK5 cascade is responsible for biliary dysgenesis in a rat model of Caroli\u2019s disease. Am. J. Pathol. 166, 49\u201360 (2005).","journal-title":"Am. J. Pathol."},{"key":"617_CR106","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1111\/j.1523-1755.2004.00952.x","volume":"66","author":"VE Torres","year":"2004","unstructured":"Torres, V. E. et al. Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats. Kidney Int. 66, 1766\u20131773 (2004).","journal-title":"Kidney Int."},{"key":"617_CR107","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/hep.21143","volume":"43","author":"L Fabris","year":"2006","unstructured":"Fabris, L. et al. Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases. Hepatology 43, 1001\u20131012 (2006).","journal-title":"Hepatology"},{"key":"617_CR108","doi-asserted-by":"publisher","first-page":"C419","DOI":"10.1152\/ajpcell.00038.2007","volume":"293","author":"CR Amura","year":"2007","unstructured":"Amura, C. R. et al. VEGF receptor inhibition blocks liver cyst growth in pkd2WS25\/\u2212 mice. Am. J. Physiol. Cell Physiol. 293, C419\u2013C428 (2007).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"617_CR109","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1053\/j.gastro.2009.09.005","volume":"138","author":"C Spirli","year":"2010","unstructured":"Spirli, C. et al. ERK1\/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice. Gastroenterology 138, 360\u2013371.e7 (2010).","journal-title":"Gastroenterology"},{"key":"617_CR110","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1002\/hep.23511","volume":"51","author":"C Spirli","year":"2010","unstructured":"Spirli, C. et al. Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice. Hepatology 51, 1778\u20131788 (2010).","journal-title":"Hepatology"},{"key":"617_CR111","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2353\/ajpath.2008.070293","volume":"172","author":"D Alvaro","year":"2008","unstructured":"Alvaro, D. et al. Morphological and functional features of hepatic cyst epithelium in autosomal dominant polycystic kidney disease. Am. J. Pathol. 172, 321\u2013332 (2008).","journal-title":"Am. J. Pathol."},{"key":"617_CR112","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/ndt\/gfq384","volume":"26","author":"C Renken","year":"2011","unstructured":"Renken, C., Fischer, D., Kundt, G., Gretz, N. & Haffner, D. Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats. Nephrol. Dial. Transplant. 26, 92\u2013100 (2011).","journal-title":"Nephrol. Dial. Transplant."},{"key":"617_CR113","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087660","volume":"9","author":"XS Ren","year":"2014","unstructured":"Ren, X. S. et al. Activation of the PI3K\/mTOR pathway is involved in cystic proliferation of cholangiocytes of the PCK rat. PLoS ONE 9, e87660 (2014).","journal-title":"PLoS ONE"},{"key":"617_CR114","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1053\/jhep.2002.34741","volume":"36","author":"D Alvaro","year":"2002","unstructured":"Alvaro, D. et al. Intracellular pathways mediating estrogen-induced cholangiocyte proliferation in the rat. Hepatology 36, 297\u2013304 (2002).","journal-title":"Hepatology"},{"key":"617_CR115","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/hep.23386","volume":"51","author":"K Isse","year":"2010","unstructured":"Isse, K. et al. Estrogen stimulates female biliary epithelial cell interleukin-6 expression in mice and humans. Hepatology 51, 869\u2013880 (2010).","journal-title":"Hepatology"},{"key":"617_CR116","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-16686-7","volume":"7","author":"LA Fatima","year":"2017","unstructured":"Fatima, L. A. et al. Estrogen receptor 1 (ESR1) regulates VEGFA in adipose tissue. Sci. Rep. 7, 16716 (2017).","journal-title":"Sci. Rep."},{"key":"617_CR117","first-page":"27","volume":"1","author":"A Franchitto","year":"2013","unstructured":"Franchitto, A. et al. Recent advances on the mechanisms regulating cholangiocyte proliferation and the significance of the neuroendocrine regulation of cholangiocyte pathophysiology. Ann. Transl. Med. 1, 27 (2013).","journal-title":"Ann. Transl. Med."},{"key":"617_CR118","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.3748\/wjg.v12.i22.3496","volume":"12","author":"JM Banales","year":"2006","unstructured":"Banales, J. M., Prieto, J. & Medina, J. F. Cholangiocyte anion exchange and biliary bicarbonate excretion. World J. Gastroenterol. 12, 3496\u20133511 (2006).","journal-title":"World J. Gastroenterol."},{"key":"617_CR119","first-page":"71","volume":"108","author":"D Li","year":"2016","unstructured":"Li, D. et al. Overexpression of aquaporin 1 on cysts of patients with polycystic liver disease. Rev. Esp. Enferm. Dig. 108, 71\u201378 (2016).","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"617_CR120","doi-asserted-by":"publisher","first-page":"F1089","DOI":"10.1152\/ajprenal.00242.2012","volume":"303","author":"X Wang","year":"2012","unstructured":"Wang, X. et al. Insignificant effect of secretin in rodent models of polycystic kidney and liver disease. Am. J. Physiol. Ren. Physiol. 303, F1089\u2013F1098 (2012).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"617_CR121","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.clinre.2018.03.009","volume":"42","author":"L Ehrlich","year":"2018","unstructured":"Ehrlich, L. et al. Biliary epithelium: a neuroendocrine compartment in cholestatic liver disease. Clin. Res. Hepatol. Gastroenterol. 42, 296\u2013305 (2018).","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"617_CR122","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/joim.12645","volume":"282","author":"L Bankir","year":"2017","unstructured":"Bankir, L., Bichet, D. & Morgenthaler, N. Vasopressin: physiology, assessment and osmosensation. J. Intern. Med. 282, 284\u2013297 (2017).","journal-title":"J. Intern. Med."},{"key":"617_CR123","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/nm935","volume":"9","author":"VH Gattone","year":"2003","unstructured":"Gattone, V. H., Wang, X., Harris, P. C. & Torres, V. E. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat. Med. 9, 1323\u20131326 (2003).","journal-title":"Nat. Med."},{"key":"617_CR124","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1681\/ASN.2004121090","volume":"16","author":"X Wang","year":"2005","unstructured":"Wang, X., Gattone, V., Harris, P. C. & Torres, V. E. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J. Am. Soc. Nephrol. 16, 846\u2013851 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"key":"617_CR125","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/labinvest.2016.93","volume":"96","author":"R Mancinelli","year":"2016","unstructured":"Mancinelli, R. et al. Vasopressin regulates the growth of the biliary epithelium in polycystic liver disease. Lab. Invest. 96, 1147\u20131155 (2016).","journal-title":"Lab. Invest."},{"key":"617_CR126","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000477664","volume":"7","author":"H Mizuno","year":"2017","unstructured":"Mizuno, H. et al. Tolvaptan for the treatment of enlarged polycystic liver disease. Case Rep. Nephrol. Dial. 7, 108\u2013111 (2017).","journal-title":"Case Rep. Nephrol. Dial."},{"key":"617_CR127","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41575-019-0125-y","volume":"16","author":"JM Banales","year":"2019","unstructured":"Banales, J. M. et al. Cholangiocyte pathobiology. Nat. Rev. Gastroenterol. Hepatol. 16, 269\u2013281 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"617_CR128","doi-asserted-by":"publisher","first-page":"G725","DOI":"10.1152\/ajpgi.90265.2008","volume":"295","author":"A Masyuk","year":"2008","unstructured":"Masyuk, A. et al. Cholangiocyte primary cilia are chemosensory organelles that detect biliary nucleotides via P2Y12 purinergic receptors. Am. J. Physiol. Gastrointest. Liver Physiol. 295, G725\u201334 (2008).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"617_CR129","doi-asserted-by":"publisher","first-page":"19138","DOI":"10.1073\/pnas.0705964104","volume":"104","author":"S Gradilone","year":"2007","unstructured":"Gradilone, S. et al. Cholangiocyte cilia express TRPV4 and detect changes in luminal tonicity inducing bicarbonate secretion. Proc. Natl Acad. Sci. USA 104, 19138\u201319143 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"617_CR130","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1083\/jcb.201101005","volume":"193","author":"T Kobayashi","year":"2011","unstructured":"Kobayashi, T. & Dynlacht, B. Regulating the transition from centriole to basal body. J. Cell Biol. 193, 435\u2013444 (2011).","journal-title":"J. Cell Biol."},{"key":"617_CR131","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13630-015-0021-1","volume":"4","author":"I Izawa","year":"2015","unstructured":"Izawa, I., Goto, H., Kasahra, K. & Inagaki, M. Current topics of functional links between primary cilia and cell cycle. Cilia 4, 12 (2015).","journal-title":"Cilia"},{"key":"617_CR132","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.gastro.2003.09.001","volume":"125","author":"T Masyuk","year":"2003","unstructured":"Masyuk, T. et al. Defects in cholangiocyte fibrocystin expression and ciliary structure in the PCK rat. Gastroenterology 125, 1303\u20131310 (2003).","journal-title":"Gastroenterology"},{"key":"617_CR133","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/S0002-9440(10)63427-X","volume":"165","author":"T Masyuk","year":"2004","unstructured":"Masyuk, T. et al. Biliary dysgenesis in the PCK rat, an orthologous model of autosomal recessive polycystic kidney disease. Am. J. Pathol. 165, 1719\u20131730 (2004).","journal-title":"Am. J. Pathol."},{"key":"617_CR134","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.2353\/ajpath.2010.090658","volume":"176","author":"A Stroope","year":"2010","unstructured":"Stroope, A. et al. Hepato-renal pathology in Pkd2ws25\/\u2212 mice, an animal model of autosomal dominant polycystic kidney disease. Am. J. Pathol. 176, 1282\u20131291 (2010).","journal-title":"Am. J. Pathol."},{"key":"617_CR135","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/path.5685","volume":"254","author":"W Wang","year":"2021","unstructured":"Wang, W. et al. IFT-A deficiency in juvenile mice impairs biliary development and exacerbates ADPKD liver disease. J. Pathol. 254, 289\u2013302 (2021).","journal-title":"J. Pathol."},{"key":"617_CR136","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/ng.2715","volume":"45","author":"M Ma","year":"2013","unstructured":"Ma, M., Tian, X., Igarashi, P., Pazour, G. J. & Somlo, S. Loss of cilia suppresses cyst growth in genetic models of autosomal dominant polycystic kidney disease. Nat. Genet. 45, 1004\u20131012 (2013).","journal-title":"Nat. Genet."},{"key":"617_CR137","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.kint.2020.05.049","volume":"98","author":"L Shao","year":"2020","unstructured":"Shao, L. et al. Genetic reduction of cilium length by targeting intraflagellar transport 88 protein impedes kidney and liver cyst formation in mouse models of autosomal polycystic kidney disease. Kidney Int. 98, 1225\u20131241 (2020).","journal-title":"Kidney Int."},{"key":"617_CR138","doi-asserted-by":"publisher","first-page":"962","DOI":"10.34067\/KID.0001022019","volume":"1","author":"AR Gallagher","year":"2020","unstructured":"Gallagher, A. R. & Somlo, S. Loss of cilia does not slow liver disease progression in mouse models of autosomal recessive polycystic kidney disease. Kidney360 1, 962\u2013968 (2020).","journal-title":"Kidney360"},{"key":"617_CR139","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ajpath.2013.09.021","volume":"184","author":"TV Masyuk","year":"2014","unstructured":"Masyuk, T. V. et al. Centrosomal abnormalities characterize human and rodent cystic cholangiocytes and are associated with Cdc25A overexpression. Am. J. Pathol. 184, 110\u2013121 (2014).","journal-title":"Am. J. Pathol."},{"key":"617_CR140","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.cell.2014.03.061","volume":"157","author":"A Szyk","year":"2014","unstructured":"Szyk, A. et al. Molecular basis for age-dependent microtubule acetylation by tubulin acetyltransferase. Cell 157, 1405\u20131415 (2014).","journal-title":"Cell"},{"key":"617_CR141","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.cell.2007.04.035","volume":"129","author":"EN Pugacheva","year":"2007","unstructured":"Pugacheva, E. N., Jablonski, S. A., Hartman, T. R., Henske, E. P. & Golemis, E. A. HEF1-dependent Aurora A activation induces disassembly of the primary cilium. Cell 129, 1351\u20131363 (2007).","journal-title":"Cell"},{"key":"617_CR142","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.ajpath.2013.11.027","volume":"184","author":"S Gradilone","year":"2014","unstructured":"Gradilone, S. et al. HDAC6 is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesis. Am. J. Pathol. 184, 600\u2013608 (2014).","journal-title":"Am. J. Pathol."},{"key":"617_CR143","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.ajpath.2017.12.016","volume":"188","author":"M Lorenzo Pisarello","year":"2018","unstructured":"Lorenzo Pisarello, M. et al. Combination of a histone deacetylase 6 inhibitor and a somatostatin receptor agonist synergistically reduces hepatorenal cystogenesis in an animal model of polycystic liver disease. Am. J. Pathol. 188, 981\u2013994 (2018).","journal-title":"Am. J. Pathol."},{"key":"617_CR144","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/hep.31216","volume":"73","author":"FJ Caballero-Camino","year":"2021","unstructured":"Caballero-Camino, F. J. et al. Synthetic conjugates of ursodeoxycholic acid inhibit cystogenesis in experimental models of polycystic liver disease. Hepatology 73, 186\u2013203 (2021).","journal-title":"Hepatology"},{"key":"617_CR145","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.kint.2016.05.031","volume":"90","author":"X Li","year":"2016","unstructured":"Li, X., Qi, N., Li, L., Wu, M. & Mei, C. Cytosolic HDAC6 is accumulated in cystic kidneys. Kidney Int. 90, 705 (2016).","journal-title":"Kidney Int."},{"key":"617_CR146","doi-asserted-by":"publisher","first-page":"17897","DOI":"10.1074\/jbc.M117.803775","volume":"292","author":"MK Yanda","year":"2017","unstructured":"Yanda, M. K., Liu, Q., Cebotaru, V., Guggino, W. B. & Cebotaru, L. Histone deacetylase 6 inhibition reduces cysts by decreasing cAMP and Ca2+ in knock-out mouse models of polycystic kidney disease. J. Biol. Chem. 292, 17897\u201317908 (2017).","journal-title":"J. Biol. Chem."},{"key":"617_CR147","doi-asserted-by":"publisher","first-page":"F997","DOI":"10.1152\/ajprenal.00186.2017","volume":"313","author":"MK Yanda","year":"2017","unstructured":"Yanda, M. K., Liu, Q. & Cebotaru, L. An inhibitor of histone deacetylase 6 activity, ACY-1215, reduces cAMP and cyst growth in polycystic kidney disease. Am. J. Physiol. Ren. Physiol. 313, F997\u2013F1004 (2017).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"617_CR148","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1086\/368295","volume":"72","author":"A Li","year":"2003","unstructured":"Li, A. et al. Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease. Am. J. Hum. Genet. 72, 691\u2013703 (2003).","journal-title":"Am. J. Hum. Genet."},{"key":"617_CR149","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1111\/liv.14485","volume":"40","author":"A Santos-Laso","year":"2020","unstructured":"Santos-Laso, A. et al. Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: new therapeutic targets. Liver Int. 40, 1670\u20131685 (2020).","journal-title":"Liver Int."},{"key":"617_CR150","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41580-018-0068-0","volume":"19","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi, L., Yamazaki, T. & Kroemer, G. Linking cellular stress responses to systemic homeostasis. Nat. Rev. Mol. Cell Biol. 19, 731\u2013745 (2018).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"617_CR151","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2007194118","volume":"118","author":"K M\u00fcller","year":"2021","unstructured":"M\u00fcller, K. et al. JNK signaling prevents biliary cyst formation through a CASPASE-8\u2013dependent function of RIPK1 during aging. Proc. Natl Acad. Sci. USA 118, e2007194118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"617_CR152","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jhep.2020.09.010","volume":"74","author":"PY Lee-Law","year":"2021","unstructured":"Lee-Law, P. Y. et al. Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models. J. Hepatol. 74, 394\u2013406 (2021).","journal-title":"J. Hepatol."},{"key":"617_CR153","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/ueg2.12126","volume":"9","author":"PY Lee-Law","year":"2021","unstructured":"Lee-Law, P. Y. et al. Inhibition of NAE-dependent protein hyper-NEDDylation in cystic cholangiocytes halts cystogenesis in experimental models of polycystic liver disease. United European Gastroenterol. J. 9, 848\u2013859 (2021).","journal-title":"United European Gastroenterol. J."},{"key":"617_CR154","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/hep.28933","volume":"65","author":"I Zubiete-Franco","year":"2017","unstructured":"Zubiete-Franco, I. et al. Deregulated neddylation in liver fibrosis. Hepatology 65, 694\u2013709 (2017).","journal-title":"Hepatology"},{"key":"617_CR155","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/hep.29577","volume":"67","author":"AI Masyuk","year":"2018","unstructured":"Masyuk, A. I. et al. Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target. Hepatology 67, 1088\u20131108 (2018).","journal-title":"Hepatology"},{"key":"617_CR156","doi-asserted-by":"publisher","first-page":"748","DOI":"10.4161\/auto.7.7.15822","volume":"7","author":"J Yang","year":"2011","unstructured":"Yang, J. et al. Deficiency of hepatocystin induces autophagy through an mTOR-dependent pathway. Autophagy 7, 748\u2013759 (2011).","journal-title":"Autophagy"},{"key":"617_CR157","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1038\/s41467-020-18794-x","volume":"11","author":"J Winkler","year":"2020","unstructured":"Winkler, J., Abisoye-Ogunniyan, A., Metcalf, K. J. & Werb, Z. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat. Commun. 11, 5120 (2020).","journal-title":"Nat. Commun."},{"key":"617_CR158","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1172\/JCI93557","volume":"128","author":"J Herrera","year":"2018","unstructured":"Herrera, J., Henke, C. A. & Bitterman, P. B. Extracellular matrix as a driver of progressive fibrosis. J. Clin. Invest. 128, 45\u201353 (2018).","journal-title":"J. Clin. Invest."},{"key":"617_CR159","doi-asserted-by":"publisher","first-page":"dev175596","DOI":"10.1242\/dev.175596","volume":"147","author":"DAC Walma","year":"2020","unstructured":"Walma, D. A. C. & Yamada, K. M. The extracellular matrix in development. Development 147, dev175596 (2020).","journal-title":"Development"},{"key":"617_CR160","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.devcel.2010.01.011","volume":"18","author":"K Si-Tayeb","year":"2010","unstructured":"Si-Tayeb, K., Lemaigre, F. P. & Duncan, S. A. Organogenesis and development of the liver. Dev. Cell 18, 175\u2013189 (2010).","journal-title":"Dev. Cell"},{"key":"617_CR161","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/nbt.3294","volume":"33","author":"M Ogawa","year":"2015","unstructured":"Ogawa, M. et al. Directed differentiation of cholangiocytes from human pluripotent stem cells. Nat. Biotechnol. 33, 853\u2013861 (2015).","journal-title":"Nat. Biotechnol."},{"key":"617_CR162","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.bbrc.2016.04.075","volume":"474","author":"K Takayama","year":"2016","unstructured":"Takayama, K. et al. Laminin 411 and 511 promote the cholangiocyte differentiation of human induced pluripotent stem cells. Biochem. Biophys. Res. Commun. 474, 91\u201396 (2016).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"617_CR163","doi-asserted-by":"publisher","first-page":"12220","DOI":"10.1038\/s41598-018-30433-6","volume":"8","author":"PL Lewis","year":"2018","unstructured":"Lewis, P. L. et al. Complex bile duct network formation within liver decellularized extracellular matrix hydrogels. Sci. Rep. 8, 12220 (2018).","journal-title":"Sci. Rep."},{"key":"617_CR164","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nbt.3275","volume":"33","author":"F Sampaziotis","year":"2015","unstructured":"Sampaziotis, F. et al. Cholangiocytes derived from human induced pluripotent stem cells for disease modeling and drug validation. Nat. Biotechnol. 33, 845\u2013852 (2015).","journal-title":"Nat. Biotechnol."},{"key":"617_CR165","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1136\/gutjnl-2013-305281","volume":"63","author":"AD Urribarri","year":"2014","unstructured":"Urribarri, A. D. et al. Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases. Gut 63, 1658\u20131667 (2014).","journal-title":"Gut"},{"key":"617_CR166","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/hep.28382","volume":"63","author":"L Locatelli","year":"2016","unstructured":"Locatelli, L. et al. Macrophage recruitment by fibrocystin-defective biliary epithelial cells promotes portal fibrosis in congenital hepatic fibrosis. Hepatology 63, 965\u2013982 (2016).","journal-title":"Hepatology"},{"key":"617_CR167","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cellimm.2015.01.018","volume":"294","author":"S Kovats","year":"2015","unstructured":"Kovats, S. Estrogen receptors regulate innate immune cells and signaling pathways. Cell. Immunol. 294, 63\u201369 (2015).","journal-title":"Cell. Immunol."},{"key":"617_CR168","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1002\/hep.24036","volume":"52","author":"J Drenth","year":"2010","unstructured":"Drenth, J., Chrispijn, M., Nagorney, D., Kamath, P. & Torres, V. Medical and surgical treatment options for polycystic liver disease. Hepatology 52, 2223\u20132230 (2010).","journal-title":"Hepatology"},{"key":"617_CR169","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1007\/s10620-007-0121-x","volume":"53","author":"L van Keimpema","year":"2008","unstructured":"van Keimpema, L., de Koning, D., Strijk, S. & Drenth, J. Aspiration-sclerotherapy results in effective control of liver volume in patients with liver cysts. Dig. Dis. Sci. 53, 2251\u20132257 (2008).","journal-title":"Dig. Dis. Sci."},{"key":"617_CR170","first-page":"409","volume":"83","author":"K Moorthy","year":"2001","unstructured":"Moorthy, K., Mihssin, N. & Houghton, P. W. J. The management of simple hepatic cysts: sclerotherapy or laparoscopic fenestration. Ann. R. Coll. Surg. Engl. 83, 409\u2013414 (2001).","journal-title":"Ann. R. Coll. Surg. Engl."},{"key":"617_CR171","doi-asserted-by":"publisher","first-page":"975.e11","DOI":"10.1016\/j.crad.2019.08.009","volume":"74","author":"J Yan","year":"2019","unstructured":"Yan, J. et al. Transarterial embolisation with bleomycin and N-butyl-2-cyanoacrylate\u2013lipiodol mixture for symptomatic polycystic liver disease: preliminary experience. Clin. Radiol. 74, 975.e11\u2013975.e16 (2019).","journal-title":"Clin. Radiol."},{"key":"617_CR172","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.4103\/0366-6999.211882","volume":"130","author":"J Zhang","year":"2017","unstructured":"Zhang, J. et al. Transarterial embolization for treatment of symptomatic polycystic liver disease: more than 2-year follow-up. Chin. Med. J. 130, 1938\u20131944 (2017).","journal-title":"Chin. Med. J."},{"key":"617_CR173","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1016\/j.radcr.2021.04.066","volume":"16","author":"T Imagami","year":"2021","unstructured":"Imagami, T., Takayama, S., Maeda, Y., Sakamoto, M. & Kani, H. Transcatheter arterial embolization for hemorrhagic rupture of a simple hepatic cyst: a case report. Radiol. Case Rep. 16, 1956\u20131960 (2021).","journal-title":"Radiol. Case Rep."},{"key":"617_CR174","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s11605-007-0376-8","volume":"12","author":"L Van Keimpema","year":"2008","unstructured":"Van Keimpema, L., Ruurda, J. P., Ernst, M. F., Van Geffen, H. J. A. A. & Drenth, J. P. H. Laparoscopic fenestration of liver cysts in polycystic liver disease results in a median volume reduction of 12.5%. J. Gastrointest. Surg. 12, 477\u2013482 (2008).","journal-title":"J. Gastrointest. Surg."},{"key":"617_CR175","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/hepr.12560","volume":"46","author":"J Yang","year":"2016","unstructured":"Yang, J. et al. Comparison of volume-reductive therapies for massive polycystic liver disease in autosomal dominant polycystic kidney disease. Hepatol. Res. 46, 183\u2013191 (2016).","journal-title":"Hepatol. Res."},{"key":"617_CR176","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1016\/j.transproceed.2008.02.080","volume":"40","author":"O Kornasiewicz","year":"2008","unstructured":"Kornasiewicz, O., Dudek, K., Bugajski, M., Najnigier, B. & Krawczyk, M. Choice of transplantation techniques and indications for liver transplantation in polycystic liver disease in patients with no signs of end-stage liver disease. Transplant. Proc. 40, 1536\u20131538 (2008).","journal-title":"Transplant. Proc."},{"key":"617_CR177","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1111\/liv.13041","volume":"36","author":"C Coquillard","year":"2016","unstructured":"Coquillard, C. et al. Combined liver\u2013kidney transplantation for polycystic liver and kidney disease: analysis from the United Network for Organ Sharing dataset. Liver Int. 36, 1018\u20131025 (2016).","journal-title":"Liver Int."},{"key":"617_CR178","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.mayocp.2015.05.011","volume":"90","author":"M Hogan","year":"2015","unstructured":"Hogan, M. et al. Efficacy of 4 years of octreotide long-acting release therapy in patients with severe polycystic liver disease. Mayo Clin. Proc. 90, 1030\u20131037 (2015).","journal-title":"Mayo Clin. Proc."},{"key":"617_CR179","doi-asserted-by":"crossref","first-page":"1661-8.e1-2","DOI":"10.1053\/j.gastro.2009.07.052","volume":"137","author":"L van Keimpema","year":"2009","unstructured":"van Keimpema, L. et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 137, 1661-8.e1-2 (2009).","journal-title":"Gastroenterology"},{"key":"617_CR180","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/j.1365-2036.2011.04923.x","volume":"35","author":"M Chrispijn","year":"2012","unstructured":"Chrispijn, M. et al. The long-term outcome of patients with polycystic liver disease treated with lanreotide. Aliment. Pharmacol. Ther. 35, 266\u2013274 (2012).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"617_CR181","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1111\/liv.12726","volume":"35","author":"T Gevers","year":"2015","unstructured":"Gevers, T. et al. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial. Liver Int. 35, 1607\u20131614 (2015).","journal-title":"Liver Int."},{"key":"617_CR182","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cgh.2015.12.049","volume":"14","author":"A Pisani","year":"2016","unstructured":"Pisani, A. et al. Long-term effects of octreotide on liver volume in patients with polycystic kidney and liver disease. Clin. Gastroenterol. Hepatol. 14, 1022\u20131030.e4 (2016).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"617_CR183","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/j.cgh.2015.05.039","volume":"13","author":"F Temmerman","year":"2015","unstructured":"Temmerman, F. et al. Lanreotide reduces liver volume, but might not improve muscle wasting or weight loss, in patients with symptomatic polycystic liver disease. Clin. Gastroenterol. Hepatol. 13, 2353\u20132359.e1 (2015).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"617_CR184","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/j.gastro.2019.04.018","volume":"157","author":"R van Aerts","year":"2019","unstructured":"van Aerts, R. et al. Lanreotide reduces liver growth in patients with autosomal dominant polycystic liver and kidney disease. Gastroenterology 157, 481\u2013491.e7 (2019).","journal-title":"Gastroenterology"},{"key":"617_CR185","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1053\/j.gastro.2013.04.055","volume":"145","author":"T Gevers","year":"2013","unstructured":"Gevers, T. et al. Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data. Gastroenterology 145, 357\u2013365.e1-2 (2013).","journal-title":"Gastroenterology"},{"key":"617_CR186","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-032620","volume":"10","author":"J Griffiths","year":"2020","unstructured":"Griffiths, J., Mills, M. & Ong, A. Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis. BMJ Open 10, e032620 (2020).","journal-title":"BMJ Open"},{"key":"617_CR187","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.2215\/CJN.13661119","volume":"15","author":"M Hogan","year":"2020","unstructured":"Hogan, M. et al. Pansomatostatin agonist pasireotide long-acting release for patients with autosomal dominant polycystic kidney or liver disease with severe liver involvement: a randomized clinical trial. Clin. J. Am. Soc. Nephrol. 15, 1267\u20131278 (2020).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"617_CR188","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1007\/s00330-017-5205-1","volume":"28","author":"T Wijnands","year":"2018","unstructured":"Wijnands, T. et al. Pasireotide does not improve efficacy of aspiration sclerotherapy in patients with large hepatic cysts, a randomized controlled trial. Eur. Radiol. 28, 2682\u20132689 (2018).","journal-title":"Eur. Radiol."},{"key":"617_CR189","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/apt.13301","volume":"42","author":"M Neijenhuis","year":"2015","unstructured":"Neijenhuis, M. et al. Somatostatin analogues improve health-related quality of life in polycystic liver disease: a pooled analysis of two randomised, placebo-controlled trials. Aliment. Pharmacol. Ther. 42, 591\u2013598 (2015).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"617_CR190","doi-asserted-by":"crossref","first-page":"175628481880478","DOI":"10.1177\/1756284818804784","volume":"11","author":"R van Aerts","year":"2018","unstructured":"van Aerts, R. et al. Drug holiday in patients with polycystic liver disease treated with somatostatin analogues. Ther. Adv. Gastroenterol. 11, 1756284818804784 (2018).","journal-title":"Ther. Adv. Gastroenterol."},{"key":"617_CR191","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev-pharmtox-010818-021059","volume":"60","author":"M Wagner","year":"2020","unstructured":"Wagner, M. & Fickert, P. Drug therapies for chronic cholestatic liver diseases. Annu. Rev. Pharmacol. Toxicol. 60, 503\u2013527 (2020).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"617_CR192","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.jhep.2016.05.009","volume":"65","author":"H D\u2019Agnolo","year":"2016","unstructured":"D\u2019Agnolo, H. et al. Ursodeoxycholic acid in advanced polycystic liver disease: a phase 2 multicenter randomized controlled trial. J. Hepatol. 65, 601\u2013607 (2016).","journal-title":"J. Hepatol."},{"key":"617_CR193","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/1744-9987.12326","volume":"20","author":"T Iijima","year":"2016","unstructured":"Iijima, T. et al. Ursodeoxycholic acid for treatment of enlarged polycystic liver. Ther. Apher. Dial. 20, 73\u201378 (2016).","journal-title":"Ther. Apher. Dial."},{"key":"617_CR194","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1681\/ASN.2004080660","volume":"16","author":"Y Tao","year":"2005","unstructured":"Tao, Y., Kim, J., Schrier, R. & Edelstein, C. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J. Am. Soc. Nephrol. 16, 46\u201351 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"key":"617_CR195","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1093\/ndt\/gfi181","volume":"21","author":"P Wahl","year":"2006","unstructured":"Wahl, P. et al. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol. Dial. Transplant. 21, 598\u2013604 (2006).","journal-title":"Nephrol. Dial. Transplant."},{"key":"617_CR196","doi-asserted-by":"publisher","first-page":"5466","DOI":"10.1073\/pnas.0509694103","volume":"103","author":"J Shillingford","year":"2006","unstructured":"Shillingford, J. et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc. Natl Acad. Sci. USA 103, 5466\u20135471 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"617_CR197","doi-asserted-by":"publisher","first-page":"5499","DOI":"10.3748\/wjg.v23.i30.5499","volume":"23","author":"F Temmerman","year":"2017","unstructured":"Temmerman, F. et al. Everolimus halts hepatic cystogenesis in a rodent model of polycystic-liver-disease. World J. Gastroenterol. 23, 5499\u20135507 (2017).","journal-title":"World J. Gastroenterol."},{"key":"617_CR198","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1056\/NEJMoa0907419","volume":"363","author":"A Serra","year":"2010","unstructured":"Serra, A. et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N. Engl. J. Med. 363, 820\u2013829 (2010).","journal-title":"N. Engl. J. Med."},{"key":"617_CR199","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1056\/NEJMoa1003491","volume":"363","author":"G Walz","year":"2010","unstructured":"Walz, G. et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 363, 830\u2013840 (2010).","journal-title":"N. Engl. J. Med."},{"key":"617_CR200","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1681\/ASN.2007050626","volume":"19","author":"Q Qian","year":"2008","unstructured":"Qian, Q. et al. Sirolimus reduces polycystic liver volume in ADPKD patients. J. Am. Soc. Nephrol. 19, 631\u2013638 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"key":"617_CR201","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jhep.2013.03.004","volume":"59","author":"M Chrispijn","year":"2013","unstructured":"Chrispijn, M. et al. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial. J. Hepatol. 59, 153\u2013159 (2013).","journal-title":"J. Hepatol."},{"key":"617_CR202","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000026797","volume":"100","author":"SE Aapkes","year":"2021","unstructured":"Aapkes, S. E., Bernts, L. H. P., van den Berg, M., Gansevoort, R. T. & Drenth, J. P. H. Tamoxifen for the treatment of polycystic liver disease: a case report. Medicine 100, e26797 (2021).","journal-title":"Medicine"},{"key":"617_CR203","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1681\/ASN.2012070650","volume":"24","author":"E Cornec-Le Gall","year":"2013","unstructured":"Cornec-Le Gall, E. et al. Type of PKD1 mutation influences renal outcome in ADPKD. J. Am. Soc. Nephrol. 24, 1006\u20131013 (2013).","journal-title":"J. Am. Soc. Nephrol."},{"key":"617_CR204","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/cge.13249","volume":"94","author":"T Fujimaru","year":"2018","unstructured":"Fujimaru, T. et al. Kidney enlargement and multiple liver cyst formation implicate mutations in PKD1\/2 in adult sporadic polycystic kidney disease. Clin. Genet. 94, 125\u2013131 (2018).","journal-title":"Clin. Genet."},{"key":"617_CR205","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s12072-021-10176-9","volume":"15","author":"H Kataoka","year":"2021","unstructured":"Kataoka, H. et al. Predicting liver cyst severity by mutations in patients with autosomal-dominant polycystic kidney disease. Hepatol. Int. 15, 791\u2013803 (2021).","journal-title":"Hepatol. Int."},{"key":"617_CR206","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3389\/fped.2017.00221","volume":"5","author":"C Bergmann","year":"2018","unstructured":"Bergmann, C. Genetics of autosomal recessive polycystic kidney disease and its differential diagnoses. Front. Pediatr. 5, 221 (2018).","journal-title":"Front. Pediatr."},{"key":"617_CR207","doi-asserted-by":"publisher","first-page":"F122","DOI":"10.1152\/ajprenal.00352.2017","volume":"314","author":"R Lakhia","year":"2018","unstructured":"Lakhia, R. et al. PPAR\u03b1 agonist fenofibrate enhances fatty acid \u03b2-oxidation and attenuates polycystic kidney and liver disease in mice. Am. J. Physiol. Ren. Physiol. 314, F122\u2013F131 (2018).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"617_CR208","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0081480","volume":"8","author":"D Yoshihara","year":"2013","unstructured":"Yoshihara, D. et al. Telmisartan ameliorates fibrocystic liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. PLoS ONE 8, e81480 (2013).","journal-title":"PLoS ONE"},{"key":"617_CR209","doi-asserted-by":"publisher","first-page":"G464","DOI":"10.1152\/ajpgi.00120.2020","volume":"320","author":"Y Sato","year":"2021","unstructured":"Sato, Y. et al. Metformin slows liver cyst formation and fibrosis in experimental model of polycystic liver disease. Am. J. Physiol. Gastrointest. Liver Physiol. 320, G464\u2013G473 (2021).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"617_CR210","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1249\/MSS.0000000000002251","volume":"52","author":"Y Sato","year":"2020","unstructured":"Sato, Y., Qiu, J., Miura, T., Kohzuki, M. & Ito, O. Effects of long-term exercise on liver cyst in polycystic liver disease model rats. Med. Sci. Sports Exerc. 52, 1272\u20131279 (2020).","journal-title":"Med. Sci. Sports Exerc."},{"key":"617_CR211","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1172\/JCI34922","volume":"118","author":"S Lee","year":"2008","unstructured":"Lee, S. et al. MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease. J. Clin. Invest. 118, 3714\u20133724 (2008).","journal-title":"J. Clin. Invest."},{"key":"617_CR212","doi-asserted-by":"publisher","first-page":"100345","DOI":"10.1016\/j.jhepr.2021.100345","volume":"3","author":"T Masyuk","year":"2021","unstructured":"Masyuk, T. et al. Autophagy-mediated reduction of miR-345 contributes to hepatic cystogenesis in polycystic liver disease. JHEP Rep. Innov. Hepatol. 3, 100345 (2021).","journal-title":"JHEP Rep. Innov. Hepatol."},{"key":"617_CR213","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1681\/ASN.2017050483","volume":"29","author":"E Cornec-Le Gall","year":"2018","unstructured":"Cornec-Le Gall, E., Torres, V. E. & Harris, P. C. Genetic complexity of autosomal dominant polycystic kidney and liver diseases. J. Am. Soc. Nephrol. 29, 13\u201323 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"617_CR214","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","volume":"393","author":"E Cornec-Le Gall","year":"2019","unstructured":"Cornec-Le Gall, E., Alam, A. & Perrone, R. D. Autosomal dominant polycystic kidney disease. Lancet 393, 919\u2013935 (2019).","journal-title":"Lancet"},{"key":"617_CR215","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/s41575-019-0156-4","volume":"16","author":"L Fabris","year":"2019","unstructured":"Fabris, L. et al. Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases. Nat. Rev. Gastroenterol. Hepatol. 16, 497\u2013511 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"617_CR216","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41572-018-0047-y","volume":"4","author":"C Bergmann","year":"2018","unstructured":"Bergmann, C. et al. Polycystic kidney disease. Nat. Rev. Dis. Primers 4, 50 (2018).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"617_CR217","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ydbio.2009.10.025","volume":"337","author":"AM Glazer","year":"2010","unstructured":"Glazer, A. M. et al. The Zn finger protein Iguana impacts Hedgehog signaling by promoting ciliogenesis. Dev. Biol. 337, 148\u2013156 (2010).","journal-title":"Dev. Biol."},{"key":"617_CR218","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1002\/hep.25872","volume":"56","author":"C Spirli","year":"2012","unstructured":"Spirli, C. et al. Cyclic AMP\/PKA-dependent paradoxical activation of Raf\/MEK\/ERK signaling in polycystin-2 defective mice treated with sorafenib. Hepatology 56, 2363\u20132374 (2012).","journal-title":"Hepatology"},{"key":"617_CR219","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1053\/j.gastro.2011.11.036","volume":"142","author":"T Masyuk","year":"2012","unstructured":"Masyuk, T. et al. Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease. Gastroenterology 142, 622\u2013633.e4 (2012).","journal-title":"Gastroenterology"},{"key":"617_CR220","doi-asserted-by":"publisher","first-page":"F465","DOI":"10.1152\/ajprenal.00460.2010","volume":"300","author":"D Yoshihara","year":"2011","unstructured":"Yoshihara, D. & et al. PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. Am. J. Physiol. Renal Physiol. 300, F465\u2013F474 (2011).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"617_CR221","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","volume":"68","author":"P Ruggenenti","year":"2005","unstructured":"Ruggenenti, P. et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int. 68, 206\u2013216 (2005).","journal-title":"Kidney Int."}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41575-022-00617-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-022-00617-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-022-00617-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,13]],"date-time":"2022-11-13T08:08:18Z","timestamp":1668326898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41575-022-00617-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,13]]},"references-count":221,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["617"],"URL":"https:\/\/doi.org\/10.1038\/s41575-022-00617-7","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,13]]},"assertion":[{"value":"7 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.M.B. received grants and consultancy from Albireo. J.P.H.D. and J.M.B. are members of the European Reference Network for Rare Liver Diseases. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}